Literature DB >> 11518711

Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF.

H Rizos1, A P Darmanian, E A Holland, G J Mann, R F Kefford.   

Abstract

The INK4a/ARF locus encodes two cell cycle regulatory proteins, the cyclin-dependent kinase inhibitor, p16(INK4a), and the p53 activator, p14(ARF). Germline mutations in this locus are associated with melanoma susceptibility in 20-40% of multiple case melanoma families. Many of these mutations specifically impair p16(INK4a), whereas mutations uniquely targeting p14(ARF) are rare. Nevertheless, the importance of p14(ARF) has not been excluded because more than 40% of INK4a/ARF alterations affect p16(INK4a) and p14(ARF). We now report that p14(ARF) is functionally impaired in melanoma kindreds carrying INK4a/ARF mutations. Of the seven INK4a/ARF mutations tested, three altered the subcellular distribution of p14(ARF) and diminished the ability of p14(ARF) to activate the p53 pathway. This work establishes the importance of p14(ARF) in melanoma predisposition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11518711     DOI: 10.1074/jbc.M105299200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death.

Authors:  Lisa M Sedger; Sarah R Osvath; Xiao-Ming Xu; Grace Li; Francis K-M Chan; John W Barrett; Grant McFadden
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 2.  Nucleolar adaptation in human cancer.

Authors:  Leonard B Maggi; Jason D Weber
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

3.  Chimeric negative regulation of p14ARF and TBX1 by a t(9;22) translocation associated with melanoma, deafness, and DNA repair deficiency.

Authors:  Xiaohui Tan; Sarah L Anzick; Sikandar G Khan; Takahiro Ueda; Gary Stone; John J Digiovanna; Deborah Tamura; Daniel Wattendorf; David Busch; Carmen C Brewer; Christopher Zalewski; John A Butman; Andrew J Griffith; Paul S Meltzer; Kenneth H Kraemer
Journal:  Hum Mutat       Date:  2013-06-03       Impact factor: 4.878

4.  CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.

Authors:  Andrew S McNeal; Kevin Liu; Vihang Nakhate; Christopher A Natale; Elizabeth K Duperret; Brian C Capell; Tzvete Dentchev; Shelley L Berger; Meenhard Herlyn; John T Seykora; Todd W Ridky
Journal:  Cancer Discov       Date:  2015-07-16       Impact factor: 39.397

5.  Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Authors:  K Laud; C Marian; M F Avril; M Barrois; A Chompret; A M Goldstein; M A Tucker; P A Clark; G Peters; V Chaudru; F Demenais; A Spatz; M W Smith; G M Lenoir; B Bressac-de Paillerets
Journal:  J Med Genet       Date:  2005-06-03       Impact factor: 6.318

6.  Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.

Authors:  Jinming Yang; Wei-Hua Pan; Gary A Clawson; Ann Richmond
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

Review 7.  DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer.

Authors:  Ruth A Gjerset
Journal:  J Mol Histol       Date:  2006-07-20       Impact factor: 2.611

8.  Assessment of functional effects of unclassified genetic variants.

Authors:  Fergus J Couch; Lene Juel Rasmussen; Robert Hofstra; Alvaro N A Monteiro; Marc S Greenblatt; Niels de Wind
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.

Authors:  Sebastian Haferkamp; Sieu L Tran; Therese M Becker; Lyndee L Scurr; Richard F Kefford; Helen Rizos
Journal:  Aging (Albany NY)       Date:  2009-05-16       Impact factor: 5.682

Review 10.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.